[ad_1]
The East Texas Heart Institute is a key contributor to a crucial and innovative study at the scientific sessions of the American Heart Association in Chicago.
"We are all delighted to share this because we put Lufkin on the national map," said Dr. Ravinder Bachireddy. "We are proud to be the third highest enrollment of all studies across the country. From all the group. "
The study's lead investigator, Dr. Christopher Cannon of Harvard Medical School, will present this study until Wednesday. HIET was considered the third largest contributor among the 21 centers participating in the study, which led Bachireddy to be named in the study. The study was also co-authored by the Baim Institute for Clinical Research and the American College of Cardiology.
The one-year comparative study of the rate of oral anticoagulant therapy in patients with non-valvular atrial fibrillation showed that more patients treated for atrial fibrillation could benefit from anticoagulant therapy. Atrial fibrillation is a very common and potentially fatal disease that is spreading in the United States, Bachireddy said. According to the American Heart Association, it manifests itself in a change of electrical impulses in the heart, in short a cardiac arrhythmia.
"This is the first study ever done by a group of doctors in Lufkin, in Deep East Texas," Bachireddy said. "And it's related to the most common arrhythmia, atrial fibrillation. This can cause heart attacks and strokes. This is a very common arrhythmia in people over 65 years old. We participated and divided the study with the largest group in Boston. "
Anti-coagulation is a way to treat AFib using anticoagulants. This prevents clot formation in case of arrhythmia, thus reducing the risk of stroke or heart failure, Bachireddy said.
The study evaluated the current use of anticoagulants in the population of people diagnosed with AFib and determined whether this would be a viable option for a larger group. Physicians associated with HIET produced candidates who were optimal to provide the study with the tests needed to evaluate the effectiveness of their hypothesis. The study examined patients' concerns regarding the use of anticoagulants, the most important concern being the risk of bleeding, reported the study.
"The study essentially helps patients with atrial fibrillation to be treated in the best possible way," Bachireddy said. "Very interesting concepts emerged from the study. The most important is to improve the care of these patients, which we did not know before the publication of this study. "
They concluded that with a conversation and a joint decision-making, doctors should be able to treat AFib patients with anticoagulants, according to the study. The concept had been considered before, but according to the study, it had not been seriously studied before this survey. The resulting results are a milestone that will have an impact on AFib care at the national level, Bachireddy said.
Because of their work and the success of this study, HIET has been offered the opportunity to pursue its research with the same groups on other heart-related issues. The following, their preparation, was offered to them by Dr. J. Brendan Mullen, Executive Vice President of the American College of Cardiology, in a letter in which he praised their work.
"Your leadership in the BOAT-AF study has paid off, with respect to the specific goals of this study as well as learning how to use the PINNACLE registry to advance cardiovascular research. We hope you will be interested in this experience and in pursuing research with ACC, "said Mullen in his letter to HIET.
The next study will focus on monitoring heart failure. HIET has started identifying the most suitable patients to participate in the study and will move on to the next phases in the next year.
[ad_2]
Source link
